Poziotinib responds 100% to pts with lung cancer mutations
By | translator Choi HeeYoung
22.09.06 12:02:07
Partner Spectrum reveals clinical trials of G778 mutation ZENITH20, which is a subtype of HER2 Exxon20 mutation
For all 12 people, the duration of partial response is 5.5 months, and PFS is 7.8 months
Poziotinib, a new lung cancer drug exported by Hanmi Pharmaceutical, was found to have a significant effect on the G778 mutation, which is common in patients with HER2 Exxon20 insertion mutation. As a result of ZENITH20 clinical subanalysis, 12 patients showed 100% response, and PFS was also longer than other HER2 Exxon20 mutants. In particular, when Poziotinib was first used, the PFS reached 9.8 months. ESMO pre-released a draft of clinical studies scheduled to be announced ahead of the opening of the academic conference on the 5th (local time). Further analysis results of ZENITH20 clinical trials conducted by Hanmi Pharmaceutical partner Spectrum Pharmaceuticals were also published.
Poziotinib is a pa
(same@dailypharm.com)
